Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.64 |
| ▸ | RXRB | P28702 | 5/20 | 0.55 |
| ▸ | RXRA | P19793 | 4/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 7/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121659 | 0.88 | PTPN1 (0.49) | PTPN1RXRBRXRAPTPN6PTPN2 | |
| SCHEMBL9247600 | 0.84 | PTPN1 (0.63) | PTPN1RXRBRXRAPTPN6PTPN2 | |
| SCHEMBL9651394 | 0.80 | PTPN1 (0.69) | PTPN1PTPN6PTPN2AKR1C2AKR1C1 | |
| SCHEMBL5437754 | 0.80 | PTPN1 (1.00) | PTPN1PTPN6PTPN2AKR1C2AKR1C1 | |
| SCHEMBL5013821 | 0.78 | MAPK14 (0.42) | PTPN1RXRBRXRAIKBKB | |
| SCHEMBL4132641 | 0.77 | IKBKB (0.47) | RXRBRXRAIKBKB | |
| SCHEMBL30388543 | 0.76 | RXRB (0.64) | RXRBRXRARXRG | |
| SCHEMBL9250549 | 0.76 | AKR1C2 (0.60) | PTPN1RXRBRXRAPTPN6PTPN2 | |
| SCHEMBL3994140 | 0.74 | PTPN1 (0.74) | PTPN1PTPN6PTPN2AKR1C2AKR1C1 | |
| SCHEMBL313198 | 0.73 | PTPN1 (0.59) | PTPN1PTPN6PTPN2AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | GLRA1, GLRB, GPBAR1 | PTPN1 1748/4885RXRB 239/4885RXRA 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.